Trevi Therapeutics, Inc.
TRVI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.14 | 0.13 | 0.06 | 0.03 |
| FCF Yield | -9.20% | -24.00% | -22.75% | -162.01% |
| EV / EBITDA | -8.02 | -3.56 | -4.33 | 0.13 |
| Quality | ||||
| ROIC | -51.15% | -40.40% | -25.61% | -102.37% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.80 | 1.09 | 0.97 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -20.23% | -12.40% | 2.11% | 0.30% |
| Safety | ||||
| Net Debt / EBITDA | 0.69 | 1.09 | 0.12 | 0.68 |
| Interest Coverage | -12,881.00 | -86.76 | -38.34 | -27.02 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |